Skip to Main Content

Author Details

Brian J Druker
Oregon Health & Science University
1978
484
116
PMIDPaper TitleJournal TitlePublished Year
37871309A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Blood Adv2024
38086008CML and the WHO: Why?J Clin Oncol2024
36264026Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.Br J Haematol2023
37890277Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.J Clin Oncol2023
37698624Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood Cancer Discov2023
37647134Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.Am J Hematol2023
37815132The FLT3<sup>N701K</sup> mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.Am J Hematol2023
37078412Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.Cancer2023
36976323Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.Mol Cancer Res2023
37199721Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.Clin Cancer Res2023
36441905Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Blood Adv2023
36526735Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.Leukemia2023
36727397Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.Haematologica2023
36315007Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Blood Adv2023
34482403Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.Blood2022
35710794Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.Nat Commun2022
35499387Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.Mol Cancer Ther2022
35590033PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.Leukemia2022
37179900Knight Scholars Program: A Tiered Three-Year Mentored Training Program for Urban and Rural High School High School Students Increases Interest and Self-Efficacy in Interprofessional Cancer Research.J STEM Outreach2022
36536477Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.Clin Transl Med2022
36734985Oncoproteomic profiling of AML: moving beyond genomics.Expert Rev Proteomics2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
36307214Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.Cold Spring Harb Mol Case Stud2022
35896960Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.Clin Proteomics2022
35195258Understanding Drug Sensitivity and Tackling Resistance in Cancer.Cancer Res2022
35078224Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.Blood Adv2022
34813325Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality.J Am Soc Mass Spectrom2022
34780648MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.Blood2022
32898857Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.Blood2021
33516272Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.Biomark Res2021
33712704Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.Oncogene2021
33707228DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.Genome Res2021
33780043A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.Am J Hematol2021
35082629Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts.Case Rep Oncol2021
34302041Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.NPJ Precis Oncol2021
34250402BCR-ABL+ Chronic Myeloid Leukemia Arising in a Family With Inherited ANKRD26-Related Thrombocytopenia.JCO Precis Oncol2021
34301758Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.Cancer Res2021
34233449Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia.Haematologica2021
34171263The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.Cancer Cell2021
34162404A precision medicine classification for treatment of acute myeloid leukemia in older patients.J Hematol Oncol2021
33997942Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.Ther Innov Regul Sci2021
33403501NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.Invest New Drugs2021
33180121Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse.JAMA Oncol2021
32366937ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.Leukemia2020
31980503Functional characterization of two rare BCR-FGFR1<sup>+</sup> leukemias.Cold Spring Harb Mol Case Stud2020
31880950Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.J Clin Oncol2020
32094466Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.Leukemia2020
33106665Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.Nat Med2020
32754299Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.Oncotarget2020
32471953Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.Proc Natl Acad Sci U S A2020
  • 1 - 50 of 484

Recommended Authors

Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 13
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 2
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 3
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 16
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 6
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 14
Mateusz Koptyra
Children's Hospital of Philadelphia
Career Start Year 2004
Number of shared co-authors 3
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 6
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 10
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 9
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 11
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 23
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 25
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 21
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 1992
Number of shared co-authors 19
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 11
Ravi Bhatia
University of Alabama at Birmingham
Career Start Year 1992
Number of shared co-authors 32
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 19
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 15
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 11
Richard J Jones
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 15
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 6
Toshio Kitamura
The University of Tokyo.
Career Start Year 1984
Number of shared co-authors 2
Jami McLaughlin
University of California los angeles
Career Start Year 1983
Number of shared co-authors 3
Donald Small
Johns Hopkins University School of Medicine
Career Start Year 1977
Number of shared co-authors 12
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 42
Wolfgang E Berdel
University Hospital Munster
Career Start Year 1976
Number of shared co-authors 12
Robin Fo??
Sapienza University.
Career Start Year 1968
Number of shared co-authors 9

Collaborators

Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 107
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 95
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 67
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 48
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 44
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 39
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 38
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 34
Bill H Chang
Oregon Health and Science University
Co-authored papers 25
Elie Traer
Oregon Health & Science University
Co-authored papers 22
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 22
Richard D Press
Oregon Health and Science University
Co-authored papers 20
Stephanie G Willis
OHSU Cancer Institute
Co-authored papers 18
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 18
Jorge Cortes
Georgia Cancer Center
Co-authored papers 17
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 17
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 17
Stephen G O'Brien
Newcastle University
Co-authored papers 16
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 16
Eric P Stoffregen
Lewis-Clark State College
Co-authored papers 15
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Kara Johnson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 13
Hamid Band
University of Nebraska Medical Center
Co-authored papers 13
Motomi Mori
St Jude Children's Research Hospital.
Co-authored papers 13
Monika A Davare
Oregon Health Sciences University
Co-authored papers 12
Theodore P Braun
Oregon Health & Science University
Co-authored papers 12
Thoralf Lange
Hospital Weissenfels
Co-authored papers 12
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 12
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 12
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 12
Release 1.2